Systemic Lupus Erythematosus (SLE) Drugs Market
Global Systemic Lupus Erythematosus (SLE) Drugs Market Size, Share & Trends Analysis Report By Treatment Types (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic, and Immunosuppressive Drugs, Biologics, and, Others), By Mode of Delivery (Intravenous, Sub-cutaneous, Oral, and Topical), Forecast 2022-2028 Update Available - Forecast 2024-2030
The global systemic lupus erythematosus (SLE) drugs market is growing at a CAGR of 7.1% during the forecast period. One of the major factors that are augmenting the growth of the systemic lupus erythematosus (SLE) drugs market is the increasing prevalence of lupus erythematosus. Furthermore, the rising geriatric population, increasing awareness of the public, and growing per capita health expenditure, are also estimated to be the other prime factors that are contributing significantly towards the growth of the market.
However, high-cost involved in treatment along with strict government rules and regulations for approval of the drug are also the major factors constraints that are hindering the growth of the global systemic lupus erythematosus (SLE) drugs market across the globe. Moreover, rising disease diagnosis and treatment in emerging regions are the key factors that are creating opportunities for the market.
Impact of COVID-19 Pandemic on Systemic Lupus Erythematosus (SLE) Drugs Market
The COVID-19 pandemic had impacted the global economy due to a slowdown in the manufacturing of various industries due to restrictions imposed by governmental bodies around the globe. The same is true for the global systemic lupus erythematosus drug market. Additionally, consumer spending was another reason as they are more concentrating on trying to eliminate non-essential expenditure from their relevant budget then. However, despite the slowdown in manufacturing and restriction on transportation systemic lupus erythematosus (SLE) drugs market is likely to recover as lockdown restrictions are lifted.
Segmental Outlook
Global systemic lupus erythematosus (SLE) drugs market is segmented on the treatment types and mode of delivery. By treatment types, the market is segmented into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs, biologics, and others (B-cell modulators, Immunosuppressive and cytotoxic drugs, T-cell modulators, Pro-inflammatory and cytokine inhibitors). Based on the mode of delivery, the market is sub-segmented into intravenous, sub-cutaneous, oral, and topical.
Global Systemic Lupus Erythematosus (SLE) Drugs Market Share by Treatment Types, 2021 (%)
The Immunosuppressive Drugs are Holding a Prominent Share in the Global Systemic Lupus Erythematosus (SLE) Drugs Market
Immunosuppressive drugs hold the significant share in the market, due to the presence of immunosuppressive drugs such as azathioprine, cyclophosphamide, and methotrexate which support in controlling inflammation and the overactive immune system in the treatment of SLE. Moreover, an increase in the popularity of methotrexate as a treatment option is likely to boost the growth of this segment.
Regional Outlooks
Global systemic lupus erythematosus (SLE) drugs market is further segmented on geography including North America (US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).
Global Systemic Lupus Erythematosus (SLE) Drugs Market Growth, by region 2022-2028
North America region is estimated to Hold the Major Share in the Global Systemic Lupus Erythematosus (SLE) Drugs Market
North America is anticipated to hold a prominent share in the market mainly due to increasing awareness about the disease in society, a growing number of foundations, and independent venture groups supporting biopharmaceutical manufacturers. Additionally, a lot of supporting factors, such as government and private sectors funding for developments, boost the demand for the drugs market in this region. Moreover, the highly structured health care industry, increasing new product adoption, and the presence of major market players will support in driving the market in North America during the forecast year.
Market Players Outlook
The major companies serving the global systemic lupus erythematosus (SLE) drugs market include Astra Zeneca PLC, GlaxoSmithKline plc., ImmuPharma PLC, Johnson and Johnson PVT Ltd., Pfizer Inc., and others. The growth of the market is considerably contributed by the market player for the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, China National Medical Products Administration (NMPA) has granted permission to GlaxoSmithKline plc Benlysta (belimumab) to treat active lupus nephritis (LN) in adults. The treatment is an inhibitor of B-lymphocyte stimulator (BLyS), Benlystais a human monoclonal antibody that attaches to soluble BLyS.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global systemic lupus erythematosus (SLE) drugs market. Based on the availability of data, information related to the market, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Systemic Lupus Erythematosus (SLE) Drugs Market
- Recovery Scenario of Global Systemic Lupus Erythematosus (SLE) Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Astra Zeneca PLC
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. GlaxoSmithkline plc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. ImmuPharma PLC
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Johnson and Johnson Pvt Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Pfizer Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Systemic Lupus Erythematosus (SLE) Drugs Market by Treatment Types
4.1.1. Antimalarial Drugs
4.1.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.1.3. Cytotoxic and Immunosuppressive Drugs
4.1.4. Biologics
4.1.5. Others (B-cell Modulators, Immunosuppressive and cytotoxic drugs, T-Cell modulators, Pro-inflammatory and Cytokine inhibitors)
4.2. Global Systemic Lupus Erythematosus (SLE) Drugs Market by Mode of Delivery
4.2.1. Intravenous
4.2.2. Sub-cutaneous
4.2.3. Oral
4.2.4. Topical
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Amgen, Inc.
6.2. Aurinia Pharmaceuticals Inc.
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. F. Hoffmann-La Roche Ltd.
6.6. Merck Group
6.7. Novartis AG
6.8. Sanofi
6.9. Teva Pharmaceutical Industries Ltd.
6.10. UCB S.A.
1. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPES, 2021-2028 ($ MILLION)
2. GLOBAL ANTIMALARIAL DRUGS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL BIOLOGICS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY MODE OF DELIVERY, 2021-2028 ($ MILLION)
8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY INTRAVENOUS RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY SUB-CUTANEOUS RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY ORAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY TOPICAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPES, 2021-2028 ($ MILLION)
15. NORTH AMERICAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY MODE OF DELIVERY, 2021-2028 ($ MILLION)
16. EUROPEAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPES, 2021-2028 ($ MILLION)
18. EUROPEAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY MODE OF DELIVERY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPES, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY MODE OF DELIVERY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPES, 2021-2028 ($ MILLION)
24. REST OF THE WORLD SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET RESEARCH AND ANALYSIS BY MODE OF DELIVERY, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET, 2022-2028 (%)
4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY TREATMENT TYPES, 2021 VS 2028 (%)
5. GLOBAL ANTIMALARIAL DRUGS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL BIOLOGICS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY MODE OF DELIVERY, 2021 VS 2028 (%)
11. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY INTRAVENOUS SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY SUB-CUTANEOUS SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY ORAL SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET BY TOPICAL SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. UK SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
